Articles related to Clinical Pharmacology

Poor metabolizers of UGT1A1 face a significantly increased risk of severe neutropenia from irinotecan therapy, making genetic testing crucial for appropriate dose modification.

The FDA-designated Class II recall affects specific duloxetine lots where exposure may lead to “temporary or medically reversible health consequences or where the probability of serious adverse health consequences is remote.”

Analysis of 285,680 patients shows a 1.03-1.38% reduction in cumulative mortality with rosuvastatin compared to atorvastatin, alongside varying risks for cardiovascular events, liver outcomes, and diabetes.

Risk of dementia with these medications increases proportionally with higher doses and extended duration of use, emphasizing the importance of minimal effective dosing strategies.

Recent data suggests that 57% of Americans over 20 take at least one dietary supplement, with multivitamins, vitamin D, and omega-3 fatty acids being the most popular choices.

Digoxin’s narrow therapeutic window and individual patient variability necessitate careful monitoring and consideration in clinical practice.